8-KEarnings & ResultsFinancial EventsRegulation FD+1

Cencora, Inc. 8-K Report, Financial Results (Jan 30, 2020)

Filed January 30, 2020For Securities:COR

Summary

Cencora, Inc. (formerly AmerisourceBergen) filed an 8-K on January 30, 2020, primarily to report on its fiscal quarter ended December 31, 2019, and to announce the significant strategic decision to exit its PharMEDium compounding business. The company is ceasing all commercial and administrative operations related to this segment due to ongoing operational, regulatory, and commercial challenges. This exit will result in substantial impairment charges and associated costs, but is also expected to generate significant tax benefits over the next few fiscal years. Investors should note that the earnings release for the quarter is incorporated by reference, and while the 8-K provides details on the disposal activities, the full financial results are available in the attached news release (Exhibit 99.1). The decision to divest PharMEDium, coupled with the associated financial implications and future tax benefits, represents a key strategic move that will shape the company's future financial performance and operational focus.

Key Highlights

  • 1Cencora (formerly AmerisourceBergen) announced the strategic decision to exit its PharMEDium compounding business.
  • 2The exit is driven by persistent operational, regulatory, and commercial challenges within the PharMEDium segment.
  • 3The company anticipates significant impairment charges for PharMEDium assets, totaling approximately $138.0 million recognized in Q1 2020 and an additional estimated impairment of $55 million (tangible) and $185 million (intangible) in Q2 2020.
  • 4Additional costs related to exiting the business, including employee separation, are estimated between $80 million and $100 million for fiscal year 2020.
  • 5The company expects to realize substantial cash tax benefits, estimated between $500 million and $600 million, from fiscal 2020 through fiscal 2022 as a result of this exit.
  • 6The 8-K incorporates by reference the earnings release for the fiscal quarter ended December 31, 2019, providing investors with a reference to the company's latest financial performance.
  • 7A conference call and webcast were scheduled for January 30, 2020, to discuss the quarterly results and related matters.

Frequently Asked Questions

Cencora is exiting the PharMEDium compounding business due to a combination of ongoing operational, regulatory, and commercial challenges. A specific trigger mentioned was PharMEDium's decision in January 2020 to suspend production at its New Jersey facility for necessary upgrades related to air handling and filtration systems.

The exit will lead to significant financial charges, including a $138.0 million impairment charge already recognized in the quarter ended December 31, 2019, and an expected additional impairment of approximately $240 million ($55 million tangible, $185 million intangible) in the following quarter. Furthermore, the company anticipates incurring $80 million to $100 million in other exit costs, such as employee separation, during fiscal year 2020. On the positive side, Cencora expects to realize substantial cash tax benefits totaling $500 million to $600 million from fiscal 2020 to fiscal 2022.

The 8-K filing incorporates by reference the news release issued on January 30, 2020, which contains the earnings announcement for the fiscal quarter ended December 31, 2019. This news release is attached as Exhibit 99.1 to the 8-K filing and is the primary source for detailed quarterly financial performance.

The 8-K contains forward-looking statements that are based on management's current expectations and are subject to uncertainties and changes in circumstances. The filing includes a cautionary note listing numerous factors that could cause actual results to differ materially from those projected. Investors should review these risk factors carefully and understand that these statements are not guarantees of future performance.